Refine Search

New Search

Advanced search

Results: 732

(searched for: Acid Reflux Discussion)
Save to Scifeed
Page of 74
Articles per Page
by
Show export options
  Select all
Sciprofile linkO. N. Minushkin, I. V. Zverkov, N. V. Lvova, Yu. S. Skibina, V. S. Inevatova
Published: 3 September 2020
Terapevticheskii arkhiv, Volume 92, pp 18-23; doi:10.26442/00403660.2020.08.000693

Abstract:
Aim. Тo evaluate the modern view on the problem of chronic gastritis and the effectiveness of the drug ursodexic acid (UHC) Grinterol in the treatment of patients with chronic antral reflux-gastritis (biliar). Materials and methods. The work provides modern ideas about chronic gastritis, the issues of etiology and pathogenesis are considered. Contemporary classifications and the attitude of the authors of the work to them are presented. Clinical studies were conducted in 50 patients with chronic antral reflux-gastritis biliary (32 women and 18 men) between the ages of 20 and 80 years (average age 50.3 to 8.0 years). The treatment uses the drug Grinterol in a daily dose of 12.5 mg/kg of body weight for 4 weeks. Results. Among patients with chronic antral gastritis isolated patients with reflux-gastritis biliary, the pathogenetic factor of which is the damaging property of aggressive bile acids. The main treatment for such patients are drugs UHC (in this study (this study uses Grinterol at a daily dose of 12.5 mg/kg of body weight); the duration of treatment is 4 years. The overall efficiency (according to endomorphological data) was 76%, according to clinical data 100%. Discussion. Critical consideration of the classifications used and proposed for consideration indicates that the time has come for the adoption of a new classification with the allocation of reflux-gastritis biliary. Treatment of this form of antral gastritis is effective with UDHC drugs. Conclusion. the selection of a form of antral reflux-gastritis biliar in a separate classification group is scientifically justified. The results suggest that for the treatment of patients with chronic biliary refluxdrugs of choice are drugs UDHC.
Amidou Tall, Karolayne Rocha Da Costa, Maria Janaína De Oliveira, Issa Tapsoba, Uéslen Rocha, Tasso O. Sales, Marília Oliveira Fonseca Goulart, Sciprofile linkJosué Carinhanha Caldas Santos
Published: 1 September 2020
Talanta; doi:10.1016/j.talanta.2020.121545

The publisher has not yet granted permission to display this abstract.
Nai-Chen Hsueh, Min-Chen Tsai, Sciprofile linkMeng-Yang Chang
Published: 25 August 2020
by Wiley
Advanced Synthesis & Catalysis; doi:10.1002/adsc.202000868

The publisher has not yet granted permission to display this abstract.
Takehiko Koga, Susumu Hijioka, Yasutake Ishikawa, Kimiteru Ito, Shota Harai, Takuji Okusaka, Yutaka Saito
Published: 20 August 2020
Endoscopy; doi:10.1055/a-1216-1220

Abstract:
Reflux cholangitis is a common complication of choledochojejunostomy [1] [2]. Intestinal content reflux is considered a possible cause for this complication when there is no stenosis at the choledochojejunal anastomosis [3] [4] [5], and post-choledochojejunostomy reflex cholangitis (PCRC) is not an indication for endoscopic procedures (e. g., stenting). Here, we discuss using antireflux self-expandable metal stents (ARMS) to treat a patient with PCRC. A 43-year-old woman who 4.5 years earlier had undergone total pancreatectomy and choledochojejunostomy (Child reconstruction) for multiple pancreatic neuroendocrine tumors presented with fever caused by PCRC. She was treated with antibiotics and ursodeoxycholic acid. However, the fever recurred two or three times a week. Computed tomography showed pneumobilia, and 99 mTc-N-pyridoxyl-5-methyltryptophan (99 mTc-PMT) hepatobiliary scintigraphy showed high tracer uptake in the afferent and blind loops. Endoscopy (CF-H260AI; Olympus Medical Systems, Tokyo, Japan) revealed that the choledochojejunal anastomosis was dilated with cholestasis. No bile duct stones were observed ([Fig. 1]). We speculated that PCRC was caused by cholestasis in the anastomosis and planned for ARMS placement. Cholangiography showed that the common hepatic duct was 23 mm in diameter; side-by-side placement of two 10-mm ARMS was considered ideal. A 7-Fr plastic stent (Harmo Ray; Hanaco Medical, Saitama, Japan) was inserted into B6 to prevent the posterior branch from being obstructed by the ARMS. Two duckbill-type ARMS (D-ARMS; 10 mm × 6 cm; Kawasumi Laboratories, Tokyo, Japan; [Fig. 2]) were placed in the anterior branch and the left hepatic duct, respectively, using the side-by-side method. To prevent stent migration, the D-ARMS were fixed to the jejunal mucosa using clips (SureClip; Micro-Tech Endoscopy, Ann Arbor, Michigan, USA) ([Fig. 3], [Fig. 4]; [Video 1]). Video 1 D-ARMS placement in a patient with refractory post-choledochojejunostomy reflux cholangitis. Hepatobiliary scintigraphy showed that cholestasis was notably reduced in the afferent and blind loops after the procedure, and the patient’s fever had improved ([Fig. 5]). This is the first report discussing D-ARMS placement in PCRC. Dramatic improvement of symptoms was observed, demonstrating that D-ARMS can serve as a new treatment for PCRC. Endoscopy_UCTN_Code_TTT_1AS_2AD Publication Date:20 August 2020 (online) © Georg Thieme Verlag KGStuttgart · New York
Veeravich Jaruvongvanich, Reem Matar, Karthik Ravi, M. Hassan Murad, Kornpong Vantanasiri, Nicha Wongjarupong, Patompong Ungprasert, Eric J. Vargas, Daniel B. Maselli, Larry J. Prokop, et al.
Clinical and Translational Gastroenterology, Volume 11; doi:10.14309/ctg.0000000000000225

Abstract:
INTRODUCTION: To assess the effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) on acid reflux and esophageal motor function and to evaluate the observation of esophageal adenocarcinoma (EAC) after bariatric surgery. METHODS: We searched 5 databases for adults who underwent SG or RYGB and had esophageal pH test and/or esophageal manometry before and after surgery. A separate systemic search of observational studies and a retrospective review at 3 institutions of adults who developed EAC after these surgeries were conducted. Outcomes were changes in manometric and pH parameters and EAC cases after SG and RYGB. RESULTS: A total of 27 nonrandomized studies (SG: 612 patients; RYGB: 470 patients) were included. After SG, lower esophageal sphincter pressure and esophageal body amplitude were decreased and the risk of ineffective esophageal motility was increased. Total and recumbent acid exposure times were increased. After RYGB, an increased risk of ineffective esophageal motility was observed. Total, upright, and recumbent acid exposure times were decreased. The total reflux episodes remained unchanged but with increased nonacid reflux and decreased acid reflux events. Including our largest series, 31 EAC cases have been reported to date after SG and RYGB. DISCUSSION: This systematic review demonstrates increased acid reflux after SG and decreased acid reflux after RYGB. An observed increased nonacid reflux after RYGB might contribute to failure of gastroesophageal reflux disease improvement. This refluxate might be noxious to the esophagus, warranting further studies. RYGB might not entirely preserve esophageal function as previously believed.
Saalim Nazki, Sciprofile linkRavi P. Kanojia, Monika Bawa, Vineet Binu, Sadhna Lal, Ashwani Sood, Ram Samujh
European Journal of Pediatric Surgery; doi:10.1055/s-0040-1713933

The publisher has not yet granted permission to display this abstract.
Michelle Kem Su Hor, Sciprofile linkMonica Dzwonkowski, Tesia Kolodziejczyk, Lorne Muir, Nazar Dubchak, Sabina Hochroth, Bhaktasharan Patel, Aaron Wu, Sean Knight, Garrett Smith, et al.
Cannabis in Medicine pp 415-451; doi:10.1007/978-3-030-45968-0_17

The publisher has not yet granted permission to display this abstract.
Serhii A. Demchenko, Yuliia A. Fedchenkova, Serhii A. Tsyhankov, Оleh E. Yadlovskyi, Volodymyr V. Sukhoveev, Tetiana A. Bukhtiarova, Ludmyla S. Bobkova, Anatolii M. Demchenko
Journal of Organic and Pharmaceutical Chemistry, Volume 18, pp 32-39; doi:10.24959/ophcj.20.193511

Abstract:
Aim. To synthesize, prove the structure and study the analgesic and anti-inflammatory activities of 3-(het)-aryl-2-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)acrylonitrile derivatives.Results and discussion. Condensation of 2-methoxy-3,4,5,6-tetrahydro-7H-azepine with cyanoacetic acid hydrazide leads to formation of 2-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)acetonitrile. The latter readily reacts with the corresponding (het)arenecarbaldehydes in refluxing ethanol in the presence of catalytic amount of piperidine yielding a series of new 3-(het)aryl-2-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)acrylonitrile derivatives. Further functionalization of 3-(4-hydroxy-3-R-phenyl)-2-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)acrylonitriles has been done by modification of the OH group. One of the compounds synthesized, namely 3-(4-hydroxyphenyl)-2-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)acrylonitrile, exhibits a high level of the analgesic activity on the “hot plate” model, and a similar level of the activity on the model of “acetic acid-induced writhings” as compared to ketorolac. The results obtained indicate the pronounced antinociceptive activity for the test compound.Experimental part. 1H NMR spectra of the compounds synthesized were recorded on a Bruker VXR-300 spectrometer (Germany) operating at a frequency of 299.945 MHz, in DMSO-d6, using tetramethylsilane (TMS) as an internal standard. Melting points were measured using a RNMK 05 device (VEB Analytik,Dresden). The elemental analysis was performed on a EuroEA 3000 elemental analyzer. The analgesic and anti-inflammatory activities of 3-(4-hydroxyphenyl)-2-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)acrylonitrile were determined using models of “carrageenan induced paw edema”, ”hot plate” and “acetic acid-induced writhings”, and compared to the reference drug ketorolac.Conclusions. A series of new 3-(het)aryl-2-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)acrylonitrile derivatives can be easily synthesized by the interaction of 2-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)acetonitrile with (het)arenecarbaldehydes. The hydroxy group in 3-(4-hydroxy-3-R-phenyl)-2-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)acrylonitriles can be modified to obtain phenyl esters of aliphatic and aromatic carboxylic acids. The high level of the analgesic activity for 3-(4-hydroxyphenyl)-2-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)acrylonitrile has been determined.Received: 30.01.2020Revised: 17.05.2020Accepted: 29.05.2020
Wenjuan Cong, Cara Swailes, Mircea Martiniuc, Wardah Talib, William Mullen, Tom Preston, Douglas J. Morrison, Emilie Combet, Christine Edwards
Proceedings of the Nutrition Society, Volume 79; doi:10.1017/s0029665120005790

Abstract:
IntroductionInteractions between polyphenols and non-digestible carbohydrates (NDC) can impact on polyphenolic metabolites bioavailability, including phenolic acids. The BLEND2 trial (NCT03840746) aims to study longer-term interactions of a flavonoid-rich food with/without NDC on microbiota metabolites and cardiometabolic markers. Trial feasibility using a bespoke food was tested.Material and MethodsThe soup was developed locally containing cherry tomatoes, tomato puree, red onion, fresh lovage, with/without the NDC inulin (10g), but improved and processed with Campden BRI, Chipping Campden, UK. The final product (~400g/ tin) was evaluated with VAS scales (0–10) for appearance, smell, taste and overall palatability, and flavonoid content evaluated using liquid chromatography-mass spectrometry. The 3-arm parallel randomised blinded design (control soup, soup + inulin, habitual diet control) recruited self-reported healthy participants (BMI > 25, 40–70y) with urine, blood, faecal samples collected at baseline, 3-week, 6-weeks.ResultsBoth soups scored similarly (n = 8 testers) for visual appeal (with inulin 5.1 ± 2.1; without 4.5 ± 2.0); smell (with 5.9 ± 1.7; without 5.4 ± 0.8); taste (with 6.6 ± 2.0; without 5.5 ± 2.3), aftertaste (with 6.3 ± 2.9; without 5.4 ± 2.3) and overall palatability (with 7.0 ± 1.9; without 6.1 ± 2.1).The soups (A&B), 1 tin/day, provide 68.5 ± 10.9 mg total flavonoids (soup A n = 3, quercetin equivalents) and 74.0 ± 16.1 mg (soup B, n = 3): quercetin (A 1.2 ± 0.1 mg; B 1.3 ± 0.6 mg), quercetin-4-glucoside (A 3.9 ± 1.0 mg; B 4.1 ± 1.9 mg), quercetin-3-rutinoside (A 23.0 ± 3.2 mg; B 20.5 ± 1.0 mg), quercetin 3,4-diglucosides (A 40.5 ± 6.9 mg; B 48.2 ± 14.9 mg).Following notes of interest (n = 415), n = 111 attended screening, n = 34 did not proceed (medications, opt-out; 31%). Participants (n = 77) are mostly British (79%), median age 56y (IQR 49-62) with a median BMI of 31 (IQR 28-35). Dropout was low (12%) and early in the study (personal issues, n = 2; gastrointestinal issues, n = 2; failure to comply with protocol, n = 2; acid reflux symptoms, n = 1; dislike of test food, n = 1). Adverse events included acid reflux/heartburn (n = 4), gastrointestinal distress (n = 3) accounting for 3 drop-outs.To date, urine, blood and faecal samples (study day or day + 1) were collected at all timepoints, for all participants. Participation (soup arms) has not led to body weight or blood lipids changes compared to control group.DiscussionThe protocol for this 6-week trial has proved feasible with lower dropout than expected. Soup flavonoid content representing ~16% of average European flavonoid intakes, with inulin (10g) half the UK daily fibre intake. The soup was well accepted with few reports of adverse issues. Recruitment in this population is challenging, due to high levels of medication and ill health.
Kathryn A. Hasenstab, Sciprofile linkSudarshan R. Jadcherla
Published: 1 June 2020
Clinics in Perinatology, Volume 47, pp 243-263; doi:10.1016/j.clp.2020.02.004

The publisher has not yet granted permission to display this abstract.
Page of 74
Articles per Page
by
Show export options
  Select all
Back to Top Top